These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23599969)

  • 21. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
    Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
    Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis.
    Dubrey SW; Patel K; Lachmann H; Sugai T; Cook T; Hill P
    Br J Hosp Med (Lond); 2016 Mar; 77(3):188-9. PubMed ID: 26961452
    [No Abstract]   [Full Text] [Related]  

  • 23. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart transplantation in cardiac amyloidosis.
    Sousa M; Monohan G; Rajagopalan N; Grigorian A; Guglin M
    Heart Fail Rev; 2017 May; 22(3):317-327. PubMed ID: 28281017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical removal of amyloid-laden lymph nodes: a possible therapeutic approach in a primary systemic AL amyloidosis patient with focal lymphadenopathy.
    Matsuda M; Katoh N; Tazawa K; Shimojima Y; Mishima Y; Sano K; Ikeda S
    Amyloid; 2011 Jun; 18(2):79-82. PubMed ID: 21401322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous Stem Cell Transplantation in Patients With Primary Systemic Amyloidosis: Experience of a Tertiary Hospital.
    Domínguez-Muñoz MA; Calderón-Cabrera C; Martino-Galiana ML; Martín-Sánchez J
    Transplant Proc; 2015 Nov; 47(9):2661-4. PubMed ID: 26680066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone.
    Kikukawa Y; Hata H; Ueda M; Yamashita T; Nasu S; Ide K; Ueno S; Ando Y; Mitsuya H; Okuno Y
    Intern Med; 2016; 55(18):2707-12. PubMed ID: 27629972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late onset renal failure and nephrotic syndrome after autologous stem cell transplant for Al amyloidosis.
    Rifkin SI; Weinstein SS
    Ren Fail; 2012; 34(5):664-6. PubMed ID: 22452410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of heart transplantation in systemic amyloidosis.
    Hawkins PN; Pepys MB
    J Heart Lung Transplant; 1996 Mar; 15(3):321-2. PubMed ID: 8777220
    [No Abstract]   [Full Text] [Related]  

  • 34. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporary Biventricular Assist Device to Bridge a Patient With Cardiogenic Shock Due to AL Amyloidosis to Heart Transplantation.
    Al-Lawati K; Lim HS
    Artif Organs; 2017 Dec; 41(12):1183-1184. PubMed ID: 29230849
    [No Abstract]   [Full Text] [Related]  

  • 36. Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis.
    Perfetto F; Casagrande S; Barilaro A; Di Gioia M; Santi R; Allinovi M; Romoli S; Boschi A; Desideri I; Taborchi G; Ungar A; Cappelli F
    Intern Emerg Med; 2021 Oct; 16(7):1927-1933. PubMed ID: 32926355
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
    Litvak A; Kumar A; Wong RJ; Smith L; Hassou H; Soff G
    Am J Hematol; 2014 Dec; 89(12):1153-4. PubMed ID: 25060940
    [No Abstract]   [Full Text] [Related]  

  • 39. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.
    Gertz MA; Lacy MQ; Dispenzieri A; Kumar SK; Buadi FK; Dingli D; Leung N; Hogan WJ; Hayman SR
    Bone Marrow Transplant; 2011 Jul; 46(7):970-5. PubMed ID: 20935685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease.
    Conner R; Hosenpud JD; Norman DJ; Pantely GA; Cobanoglu A; Starr A
    J Heart Transplant; 1988; 7(2):165-7. PubMed ID: 3284989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.